Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPARγ expression in cultured astrocytes

Brain Research

Volumn 1312, Issue , 2010, Pages 138-144

  Valles, Soraya L ^a   Dolz Gaiton, Pablo ^a   Gambini, Juan ^a   Borras, Consuelo ^a   LLoret, Ana ^a   Pallardo, Federico V ^a,b   Viña, Jose ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Alzheimer's disease; COX 2; IL 1; iNOS; PPAR; TNF

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYCLOOXYGENASE 2; ESTRADIOL; GENISTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; ANIMALS; ASTROCYTES; CELLS, CULTURED; CEREBRAL CORTEX; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGENS; GENE EXPRESSION REGULATION; GENISTEIN; INTERLEUKIN-1BETA; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDE FRAGMENTS; PPAR GAMMA; PROTEIN KINASE INHIBITORS; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73649131216     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.044     Document Type: Article

References (44)

1. Akama K.T., and Van Eldik L.J. β-Amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NFκB-inducing kinase-dependent signalin mechanism. J. Biol. Chem. 275 (2000) 7918-7924
2. Baker A.E., Brautigam V.M., and Watters J.J. Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor β. Endocrinology 145 (2004) 5021-5032
3. Bang O.Y., Hong H.S., Kim D.H., Boo J.H., Huh K., and Mook-Jung I. Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol. Dis. 16 (2004) 21-28
4. Borras C., Sastre J., Garcia-Sala D., Lloret A., Pallardo F.V., and Vina J. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic. Biol. Med. 34 (2003) 546-552
5. Borras C., Gambini J., Gomez-Cabrera M.C., Sastre J., Pallardo F.V., Mann G.E., and Vina J. 17 Beta-estradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK1 and ERK2 (MAPK)/NFkappaB cascade. Aging Cell 4 (2005) 113-118
6. Borras C., Gambini J., Gómez-Cabrera M.C., Sastre J., Pallardó F.V., Mann G.E., and Viña J. Genistein, a soy isoflavone, upregulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2 and NFkappaB. FASEB J. 20 (2006) 2136-2138
7. Chong Y.H., Sung J.H., Shin S.A., Chung J.H., and Suh Y.H. Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. J. Biol. Chem. 29 (2001) 23511-23517
8. Comalada M., Ballester I., Bailón E., Sierra S., Xaus J., Gálvez J., de Medina F.S., and Zarzuelo A. Inhibition of pro-inflammatory markers in primary bone marrow-derived Mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem. Pharmacol. 72 (2006) 1010-1021
9. Dang Z.C., Audinot V., Papapoulos S.E., Boutin J.A., and Lowik C.W. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 278 (2003) 962-967
10. Dhandapani K.M., and Brann DW. Role of astrocytes in estrogen-mediated neuroprotection. Exp. Gerontol. 52 (2007) 70-75
11. Genazzani A.R., Plunchino N., Luisi E., and Luise M. Hum. Reprod. Updat. 13 (2007) 175-187
12. Genolet R., Wahli W., and Michalik L. PPARs as drug targets to modulate inflammatory response?. Curr. Drug Targets Inflamm. Allergy 3 (2004) 361-375
13. Giunta B., Fernandez F., Nikolic W.V., Obregon D., Rrapo E., Town T., and Tan J. Inflammaging as a prodrome to Alzheimer's disease. J. Neuroinflammation 5 (2008) 51-65
14. Heneka M.T., and Landreth G.H. PPARs in the brain. Biochim. Biophys. Acta 1771 (2007) 1031-1045
15. Iwase Y., Fukata H., and Mori C. Estrogenic compounds inhibit gap junctional intercellular communication in mouse Leydig TM3 cells. Toxicol. Appl. Pharmacol. 212 (2006) 237-246
16. Koivisto A.M., Helisalmi S., Pihlajamaki J., Hiltunen M., koivisto K., Moilanen L., et al. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population. Dement. Geriatr. Cogn. Disord. 22 (2006) 449-453
17. Lu H., Shi J.X., Zhang D.M., Wang H.D., Hang C.H., Chen H.L., and Yin H.X. Inhibition of hemolysate-induced iNOS and COX-2 expression by genistein through suppression of NF-mall Ka, Cyrillic B activation in primary astrocytes. J. Neurol. Sci. 278 (2009) 91-95
18. Luth H.J., Holzer M., Gartner U., Staunfenbiel M., and Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 953 (2001) 57-67
19. Luth H.J., Munch G., and Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res. 953 (2002) 135-143
20. Ma H., Sprecher H.W., and Kolattukudy P.E. Estrogen-induced production of a peroxisome proliferator-activates receptor (PPAR) ligand in a PPARγ-expressing tissue. J. Biol. Chem. 273 (1998) 30131-30138
21. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci. 1035 (2004) 104-116
22. McGeer P.L., Rogers J., and McGeer E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. Alzheimer's Dis. 9 (2006) 271-276
23. Mahn K., Borras C., Knowck G.A., Taylor P., Khan I.Y., Sugden D., Poston L., Warde J.P., Sharpe R.M., Vina J., Aaronson P.I., and Mann G.E. Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J. 19 (2005) 1755-1757
24. Murakami A., Matsumoto K., Koshimizu K., and Ohigashi H. Effects of selected food factors with chemopreventive properties on combined lipopolysaccharide- and interferon-gamma-induced IkappaB degradation in RAW 2647 macrophages. Cancer Lett. 30 (2003) 17-25
25. Perry G., Cash A.D., and Smith M.A. Alzheimer disease and oxidative stress. J. Biomed. Biotechnol. 2 (2002) 120-123
26. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83 (1977) 346-356
27. Resnick S.M., Maki P.M., Rapp S.R., Espeland M.A., Brunner R., Coker L.H., Granek I.A., Hogan P., Ockene J.K., and Shumaker S.A. Women's Health Initiative Study of Cognitive Aging Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J. Clin. Endocrinol. Metab. 91 (2006) 1802-1810
28. Rocca W.A., Bower J.H., Maraganore D.M., Ahiskog J.E., Grossardt B.R., de Andrade M., and Melton L.J. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69 (2007) 1074-1083
29. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., and Jackson R.D. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
30. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Oximek L., Thal D.R., Landreth G., Walter J., klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 443-448
31. Sastre M., Klockgether T., and Heneka M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Inst. J. Dev. Neurosci. 24 (2006) 167-176
32. Scacchi R., Pinto A., Gambina G., Rosano A., and Corbo R.M. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res. 1139 (2007) 1-5
33. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
34. Smith M.A., Richey, Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
35. Vallés S.L., Blanco A.M., Azorin I., Guasch R., Pascual M., Gomez-Lechón M.J., Renau-Piqueras J., and Guerri C. Chronic ethanol consumption enhances IL-1-mediated signal transduction in rat liver and in cultured hepatocytes. Alcohol Clin. Exp. Res. 27 (2003) 1979-1986
36. Vallés S.L., Blanco A.M., Pascual M., and Guerri C. Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathol. 14 (2004) 365-371
37. Vallés S.L., Borrás C., Gambini J., Furriol J., Ortega A., Sastre J., Pallardo F.V., and Viña J. Oestradiol or genistein rescues neurons from amyloid beta-induced cell death by inhibiting activation of p38. Aging Cell 7 (2008) 112-118
38. Vegeto E., Belcredito S., Etteri S., Ghisletti S., Brusadelli A., Meda C., Krust A., Dupont S., Ciana P., Chambon P., and Maggi A. Estrogen receptor-alpha mediates the brain anti-inflammatory activity of estradiol. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9614-9619
39. Vegeto E., Benedusi V., and Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 29 (2008) 507-519
40. Wan H., Yuan Y., Qian A., Sun Y., and Qiao M. Pioglitazone, a PPARgamma ligand, suppresses NFkappB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed. Pharmacother. 62 (2007) 466-472
41. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 12 (2006) 1005-1015
42. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., and Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245 (1989) 417-420
43. Yu B.P., and Chung H.Y. The inflammatory process in aging. Rev. Clin. Gerontol. 16 (2007) 179-187
44. Zhu X., Su B., Wang X., Smith M.A., and Perry G. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 64 (2007) 2202-2210